DNA strands intertwined with kidney structures, symbolizing the genetic basis of diabetic nephropathy.

Decoding Diabetic Nephropathy: Is It In Your Genes?

Avery Sinclair monogram
Avery Sinclair in Health & Wellness October 2026 • 4 min read.

"Unraveling the genetic mysteries of diabetic nephropathy could revolutionize how we predict, prevent, and treat this diabetes complication."


The global rise in diabetes cases brings with it a surge in chronic complications, with diabetic nephropathy (DN) standing out as a major concern. Beyond its high occurrence, DN is linked to significant health issues, particularly heart-related problems, making it a critical area of study and prevention.

Scientists have long suspected that genetics plays a role in who develops DN. The idea is that some individuals are genetically predisposed to DN, and when exposed to certain environmental factors, they are more likely to develop the condition. This makes DN a complex puzzle, influenced by both our genes and our environment.

Researchers are on a quest to pinpoint the specific genes that contribute to DN. By identifying these genes, doctors could potentially screen individuals to determine their risk level and develop more effective, personalized treatment plans. This article explores the strategies researchers are using to find these genes and what the current evidence suggests about the genetic basis of DN.

AI Search Multiple angles on this topic

Genes Under Study

The Family Investigation of Nephropathy and Diabetes (FIND) study, together with family and MALD studies, identified several genes that contribute to diabetic nephropathy, albuminuria, and glomerular filtration rate, including ApoL1. Native American participants were excluded from FIND because consent did not permit data sharing. A 2020 systematic review and meta-analysis examined 228 genes and 606 polymorphisms related to diabetic nephropathy.

Genetic Evidence, Unresolved Mechanisms

Familial aggregation and ethnic-specific prevalence rates are cited as evidence that diabetic nephropathy has an inherent genetic basis. A 2019 review describes clinical material, research approaches, and experimental designs used in genetic and epigenetic studies of diabetic kidney disease. Despite evidence for heritability in type 1 and type 2 diabetes, the underlying mechanisms remain poorly understood, and the review reports no robust diabetic nephropathy candidate genes.

A Gradually Evolving Definition

The discovery of diabetic renal disease was gradual, and the definition of diabetic nephropathy has changed over time. A historical account traces diabetes and diabetic nephropathy across almost 4,000 years, from ancient beginnings to current therapy. The morphological changes of diabetic nephropathy were first described by Kimmelstiel and Wilson in 1936.

What Genetic Factors Make Some People More Susceptible to Diabetic Nephropathy?

DNA strands intertwined with kidney structures, symbolizing the genetic basis of diabetic nephropathy.

DN isn't caused by a single gene but likely results from a combination of multiple genes, each with a small effect, interacting with environmental factors. This complex genetic inheritance makes it challenging to identify specific genes and predict who will develop DN. Here are the primary ways scientists are working to unravel this complexity:

The candidate gene approach involves selecting genes known to play a role in processes related to DN, such as blood pressure regulation or insulin resistance, and then examining variations (polymorphisms) within those genes to see if they are more common in people with DN. Genome-wide association studies (GWS) take a broader approach, scanning the entire genome for genetic markers associated with DN, without preselecting specific genes. Each strategy has its own strengths and weaknesses:

  • Candidate Gene Approach: Focuses on specific genes of interest, but can be limited by prior knowledge and may miss novel genes.
  • Genome-Wide Association Studies (GWS): Scans the entire genome, but requires large sample sizes to detect genes with small effects and can produce many false positives.
AI Search Multiple angles on this topic

Heritability and Epigenetics

A 2024 update reports diabetic kidney disease heritability estimates ranging from 30% to 75%, depending on the trait, with higher values for more severe clinical definitions. A Nature Reviews Nephrology review dated November 21, 2025, describes current understanding of epigenetics and epigenomics in diabetic kidney disease. It examines how epigenetic mechanisms might contribute to metabolic processes in the disease.

Challenges in Detecting Associations

A genome-wide meta-analysis and omics integration study reports a lack of replication across diabetes subtypes. It suggests this could reflect false positives or insufficient power to detect rare-variant associations in type 2 diabetes, where DKD is more heterogeneous, particularly at early stages such as microalbuminuria. Separately, a type 1 diabetes study did not reach genome-wide statistical significance for a combined proteinuria/ESRD phenotype and suggested that the phenotype may have been too heterogeneous for its sample size.

Despite the challenges, both approaches have yielded some promising leads, with researchers identifying several genes that appear to be associated with DN in certain populations. However, many of these findings have been inconsistent across different studies, highlighting the need for more research to confirm these associations and identify the specific genetic variants that contribute to DN risk.

What's Next for Understanding the Genetics of Diabetic Nephropathy?

Identifying the genes involved in DN is just the first step. The ultimate goal is to use this knowledge to develop new ways to prevent and treat the disease. This could involve screening individuals at high risk, developing personalized therapies based on their genetic profile, or identifying new drug targets that address the underlying causes of DN. While there's still much work to be done, the progress in understanding the genetics of DN offers hope for a future where this serious complication can be better managed and even prevented.

AI Search Multiple angles on this topic

A Candidate Genetic Signal

An analysis published on August 19, 2025, reports that diabetic nephropathy’s genetic etiology is primarily attributed to an inherent susceptibility to kidney injury. The study identifies 10 suggestive loci, five of which it says have a high probability of being causal. Its top candidate is a missense variant in TCN2, p.K77M.

Potential Therapeutic Targets

A report dated January 25, 2026, says a research team identified several novel causal genes associated with diabetic nephropathy. It reports that these genes had not previously been implicated in the disease’s pathogenesis. The findings may offer potential therapeutic targets for further exploration in the context of diabetes management.

An Incompletely Characterized Architecture

A bioRxiv abstract dated July 1, 2026, describes diabetic nephropathy as the leading cause of kidney failure in the developed world. It also states that the genetic architecture of susceptibility to the disease is not well characterized. The work is presented as a cross-species systems genetics framework.

Risk Factors in an Educational Case

An educational case published on October 1, 2025, describes a patient with proteinuria for whom diabetic nephropathy was considered the most likely cause. The case notes longstanding type 2 diabetes with poor glycemic control, including HbA1c above 7%, as well as hypertension and hyperlipidemia. It also reports evidence of peripheral neuropathy.

Signals reported in diabetic nephropathy genetics

  • 1.24 pooled odds ratioFor ACE variant rs179975, 42 studies produced a pooled odds ratio of 1.24 (95% CI 1.12–1.37).[1]

What association estimates can tell us

These pooled estimates describe associations, not proof that either variant causes diabetic nephropathy. The ACE estimate summarizes many studies, while the CARS result is a distinct signal; neither alone explains how the disease develops.[1] [2]

A large sample can reveal signals that smaller efforts may not detect: increasing the type 1 diabetes sample to 20,000 was associated with a COL4A3 signal linked to a thinner glomerular basement membrane and protection from albuminuria and diabetic kidney disease. This is a specific reported relationship, not a complete account of inherited risk.[3]

How genetic signals vary across studies

The type 1 diabetes scan's replication choices were constrained by limited power and by efforts to control false-positive risk; it excluded SNPs below its stated significance threshold from replication. Even after replication, the FRMD3 and CARS associations required confirmation, and their biological mechanisms remained unresolved. Additional cohorts, especially non-Caucasian groups, were identified as useful for characterizing these candidate signals.[4]

In Pima Indians, analyses did not support a major gene effect on diabetes duration at nephropathy onset, and lifetime-occurrence analyses were inconclusive; imprecise dating of onset was offered as a possible reason. Separately, human kidney sample availability limits cell-specific study of epigenetic changes, leaving a practical barrier to understanding those processes.[3] [5]

What remains unresolved about inherited risk

  • Do the reported genetic associations reflect mechanisms that contribute to kidney injury, or do they mark nearby variation whose biological effects remain unknown? The need to elucidate mechanisms at FRMD3 and CARS leaves that distinction open.[4]
  • Would broader and more diverse cohorts reproduce the candidate signals, given the stated value of additional non-Caucasian cohorts for characterizing them?[4]

Sources

  1. Genetic associations in diabetic nephropathy: a meta-analysis (pmc.ncbi.nlm.nih.gov)
  2. The genetic map of diabetic nephropathy: evidence from a systematic review and meta-analysis of genetic association studies (pmc.ncbi.nlm.nih.gov)
  3. Molecular pathways that drive diabetic kidney disease (pmc.ncbi.nlm.nih.gov)
  4. Genome-Wide Association Scan for Diabetic Nephropathy Susceptibility Genes in Type 1 Diabetes (pmc.ncbi.nlm.nih.gov)
  5. Segregation analysis of diabetic nephropathy in Pima Indians. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What exactly is diabetic nephropathy, and why is it a problem?

Diabetic nephropathy (DN) is a significant complication of diabetes, characterized by kidney damage. Its importance lies in its high prevalence among diabetes patients and its association with other serious health issues, especially cardiovascular problems. Understanding DN is crucial for developing strategies to prevent and manage the condition, thereby reducing the burden on individuals and healthcare systems. Left unmanaged Diabetic Nephropathy may progress to kidney failure.

2

Why do some people with diabetes develop kidney problems while others don't?

The prevailing understanding suggests that diabetic nephropathy (DN) arises from a combination of genetic predisposition and environmental factors. Individuals may inherit genes that make them more susceptible to kidney damage when exposed to conditions such as high blood sugar levels or high blood pressure. This interplay highlights the complexity of DN, where genetic vulnerability combines with lifestyle and environmental influences to determine disease development. More research is required to understand the relationship of these factors.

3

How are scientists trying to find the genes that cause diabetic kidney disease?

Researchers employ two primary strategies to pinpoint the genes involved in diabetic nephropathy (DN): the candidate gene approach and genome-wide association studies (GWAS). The candidate gene approach focuses on specific genes already known to be involved in kidney function or diabetes-related processes. Genome-wide association studies (GWAS) scan the entire genome to identify genetic markers associated with DN. While both methods have shown promise, challenges remain, and findings often need to be validated across diverse populations.

4

If we find the genes involved in diabetic kidney disease, what good will it do?

Identifying the genes associated with diabetic nephropathy (DN) is a crucial initial step. This knowledge opens avenues for developing new strategies to prevent and treat the disease. It may enable screening individuals at high risk, tailoring treatments based on their genetic makeup, and identifying novel drug targets to address the underlying causes of DN. This understanding may lead to more effective and personalized interventions, ultimately improving patient outcomes.

5

What are the downsides of the research methods being used?

Both the candidate gene approach and genome-wide association studies (GWAS) have limitations. The candidate gene approach is limited by our existing knowledge and may miss novel genes, while genome-wide association studies (GWAS) require large sample sizes and can generate false positives. Despite these challenges, these approaches have identified several genes potentially linked to diabetic nephropathy (DN). Further research is needed to confirm these associations and pinpoint the specific genetic variants that contribute to DN risk. Further studies are also required to understand the interactions between genes and environmental factors.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.